OPKO HEALTH, INC. : Change in Directors or Principal Officers (form 8-K)
March 03, 2021 at 04:06 pm EST
Share
ITEM 5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
On March 1, 2021, the Board of Directors (the "Board") of OPKO Health, Inc., a
Delaware corporation (the "Company"), appointed Prem A. Lachman, M.D. as a new
director with immediate effect to serve until the Company's 2021 Annual Meeting
of Stockholders and until his successor shall be duly elected or appointed or
his earlier death or resignation. Dr. Lachman has not been named to any
committees of the Board at this time. There is no arrangement or understanding
between Dr. Lachman and any other persons pursuant to which Dr. Lachman was
selected as a director. The Board has determined that Dr. Lachman is independent
under the applicable rules of the Securities and Exchange Commission and the
Nasdaq Stock Market.
Dr. Lachman is a healthcare investment manager with more than 35 years of
experience in portfolio management, biopharmaceutical investment research and
healthcare investment banking. Additionally, Dr. Lachman is supported by a
foundation in medicine and gastroenterology research. Dr. Lachman founded
Maximus Capital, LLC in 1998 and currently serves as its general partner. Dr.
Lachman previously served as the general partner of The Galleon Group from 1998
to 2001 and as Managing Director, Investment Research at Goldman Sachs & Co.
from 1989 to 1998. Dr. Lachman is a Directors Council board member of the Museum
of Modern Art, a patron of the Metropolitan Opera, and a board member of the
Department of Surgery at Mount Sinai Medical Center in New York.
Since the beginning of the Company's last fiscal year, the Company has not
engaged in any transaction, or any currently proposed transaction, in which Dr.
Lachman had or will have a direct or indirect material interest that would
require disclosure pursuant to Item 404(a) of Regulation S-K promulgated by the
Securities and Exchange Commission.
Dr. Lachman will participate in the standard non-employee director compensation
arrangements described in the section entitled "Director Compensation" that is
included in the Company's 2020 Proxy Statement on Schedule 14A filed with the
Securities and Exchange Commission on April 29, 2020. The Company has also
entered into its standard director indemnification agreement with Dr. Lachman, a
form of which has been filed or incorporated by reference as Exhibit 10.3 to the
Company's Annual Report on Form 10-K for the year ended December 31, 2020 filed
with the SEC on February 18, 2021.
OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company's diagnostics segment consists of the clinical laboratory operations of BioReference Health, LLC (BioReference), its point-of-care operations. Its pharmaceutical segment consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. Through BioReference, it operates specialized laboratory divisions, such as GenPath (Urology), GenPath (Oncology), and GenPath (Women's Health). It has two commercial stage pharmaceutical products and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Rayaldee, Rayaldee, Oxyntomodulin, Biologics, NGENLA Somatrogon, and Factor VIIa-CTP. It develops and manufactures specialty active pharmaceutical ingredients (APIs) through FineTech Pharmaceutical, Ltd.
OPKO HEALTH, INC. 
